Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVID RAF: Oral vs IV Diltiazem in AF
NCT03472495Phase 4
Key facts
- Status
- Completed
- Start
- Jun 2018
- Primary completion
- Mar 2021
- Countries
- 1
- Sponsor
- Virginia Commonwealth University
- Modality
- Small Molecules
- Drugs
- diltiazem
- Conditions
- Atrial fibrillation (AFib)atrial flutter (AFL)
01
Overview
Phase 4, randomised, open-label trial of diltiazem in Atrial fibrillation (AFib) and atrial flutter (AFL) (2 arms), sponsored by Virginia Commonwealth University. Primary endpoint: Heart Rate Control at 2 hours. Started Jun 2018; status: completed.
02
Design
2 arms- Study design
- RandomizedOpen-label
Oral Immediate Release Diltiazem
Diltiazem immediate release 60mg orally once
Continuous Infusion IV Diltiazem
Diltiazem 2.5-5 mg/hour intravenous Titrate
03
Who it enrols
Adult patients with atrial fibrillation or flutter and a heart rate > 110 beats/min, excluding those with hypotension, pregnancy, WPW syndrome, or prior antiarrhythmic use.
04
Endpoints
Primary
Heart Rate Control
Secondary
Adverse Event Rate
Beyond the preview
Go deeper on NCT03472495.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03472495.